Stakeholders’ Perspectives Toward the Use of Patient Registry Data for Decision-Making on Medicines: A Cross-Sectional Survey
The participants in our survey were generally open to increasing the use of registry data in the future. Nevertheless, perceived weaknesses such as data quality and accessibility will need to be addressed to align and improve stakeholders' perspectives on the use of patient registries as an evidence basis for medicines decision-making.
Authors
- Peter G. M. Mol (ORCID: https://orcid.org/0000-0002-4262-3180)
- Carla Torre (ORCID: https://orcid.org/0000-0002-5542-9993)
- Sieta T. de Vries (ORCID: https://orcid.org/0000-0001-6090-2434)
- Björn Wettermark (ORCID: https://orcid.org/0000-0003-0531-2516)
- Bruno Sepodes (ORCID: https://orcid.org/0000-0002-2761-0955)
- Diogo Fraxino de Almeida (ORCID: https://orcid.org/0009-0004-5648-2800)
- Fabian Windfuhr (ORCID: https://orcid.org/0009-0003-6065-2860)
- Tanja Dahlqvist
- Maria Melinder
Institutions
- Uppsala University (SE)
- University Medical Center Groningen (NL)
- University of Lisbon (PT)
- University of Groningen (NL)
- Medicines Evaluation Board (NL)
Publication Details
- Journal
- Drug Safety
- Published
- 2025-02-23
- DOI
- https://doi.org/10.1007/s40264-025-01528-7
- Citations
- 3
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 9.39
Funders
- HORIZON EUROPE Framework Programme